Why Attend Europe’s Obesity Drug Development Summit?
The 2025 inaugural Obesity Drug Development Summit Europe was the definitive forum for pharmaceutical leaders, biotech innovators, and academic pioneers driving the next wave of metabolic therapies.
This summit united 50+ industry experts to tackle critical challenges in obesity drug development, from novel targets and clinical trial design to manufacturing breakthroughs and payer strategies. Whether you’re exploring GLP-1 combinations, RNA-based platforms, or real-world evidence, this was your chance to shape the future of a $100 billion market.
2025 Event Highlights
We have handpicked some of the key topics on the 2025 agenda, all designed to help you advance next-generation obesity therapies to patients faster.
Unlock Next-Gen Targets
Dive into pioneering research on GIPR modulators, mitochondrial activators, and DNA-encoded therapies to transform metabolic outcomes.
Optimise Clinical Trials
Learn to leverage biomarkers, precision dosing, and patient-centric endpoints for faster approvals and reimbursement.
Master Combination Therapies
Discover strategies to preserve lean mass and enhance efficacy with GLP-1/myostatin-amylin combos.
Exclusive Networking
Connect with 50+ decision-makers from Novo Nordisk, Eli Lilly, and Boehringer Ingelheim during curated sessions.
Navigate Manufacturing Challenges
Gain insights into oral formulations and extended-release injectables to overcome production bottlenecks.
Attending Companies Included